ArticleBiochimica et biophysica acta. Molecular basis of disease2023
d-Alanine as a biomarker and a therapeutic option for severe influenza virus infection and COVID-19.
Article in Biochimica et biophysica acta. Molecular basis of disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Identification of disease ameliorated metabolite candidates from Gut Microbes and their interacting targets based on a novel estimating function.Frontiers in microbiology · 2026Article
- Theoretical Analysis of d-Serine and d-Asparagine as Biomarkers for Glomerular Filtration Rate.Chemistry & biodiversity · 2025Review
- Impact of D-Amino Acids in Schizophrenia.Biomolecules · 2025Review
- Detection of Fast Decliner of Diabetic Kidney Disease Using Chiral Amino Acid Profiling: A Pilot Study.Chemistry & biodiversity · 2025Article
- d-Alanine, a Circadian Metabolite that Regulates Glucose Metabolism and Viral Infection.Chembiochem : a European journal of chemical biology · 2025Review
- Bioactive Molecules from Tropical American Plants: Potential Anti-Inflammatory Agents for Cytokine Storm Management.Molecules (Basel, Switzerland) · 2025Review
- Multiomics analysis unveils key biomarkers during dynamic progress of IAV infection in mice.Frontiers in immunology · 2025Article
- Kinetic analysis of D-Alanine upon oral intake in humans.Amino acids · 2024Article
- Sulfated Bile Acids in Serum as Potential Biomarkers of Disease Severity and Mortality in COVID-19.Cells · 2024Article
- Viral entry and translation in brain endothelia provoke influenza-associated encephalopathy.Acta neuropathologica · 2024Article
- The gut-joint axis mediates the TNF-induced RA process and PBMT therapeutic effects through the metabolites of gut microbiota.Gut microbes · 2023Article
- D-Serine as a sensor and effector of the kidney.Clinical and experimental nephrology · 2023Review
- Blood levels of d-amino acids reflect the clinical course of COVID-19.Biochemistry and biophysics reports · 2023Article
- D-Asparagine is an Ideal Endogenous Molecule for Measuring the Glomerular Filtration Rate.Kidney international reports · 2023Article
- Salivary Metabolomic Analysis Reveals Amino Acid Metabolism Shift in SARS-CoV-2 Virus Activity and Post-Infection Condition.Metabolites · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the outbreak of coronavirus disease 2019 (COVID-19), biomarkers for evaluating severity, as well as supportive care to improve clinical course, remain insufficient. We explored the potential of d-amino acids, rare enantiomers of amino acids, as biomarkers for assessing disease severity and as protective nutrients against severe viral infections. In mice infected with influenza A virus (IAV) and in patients with severe COVID-19 requiring artificial ventilation or extracorporeal membrane oxygenation, blood levels of d-amino acids, including d-alanine, were reduced significantly compared with those of uninfected mice or healthy controls. In mice models of IAV infection or COVID-19, supplementation with d-alanine alleviated severity of clinical course, and mice with sustained blood levels of d-alanine showed favorable prognoses. In severe viral infections, blood levels of d-amino acids, including d-alanine, decrease, and supplementation with d-alanine improves prognosis. d-Alanine has great potentials as a biomarker and a therapeutic option for severe viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.